ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc (OTCQX:ANPCY) has appointed Joseph Eid M.D. as Non-Executive Director, effective January 19, 2023. Dr. Eid, a certified oncologist with over 25 years of experience in clinical trials and drug development, previously held senior roles at major pharmaceutical firms including Merck and Bristol Myers Squibb. His significant contributions include leading the global strategy for Keytruda, enhancing the company’s focus on oncology biomarkers and clinical applications. Both Dr. Eid and the company aim to leverage his expertise to advance ANGLE’s liquid biopsy technology and commercial strategy.

ANGLE plc has reported a change in major holdings, as Aegon NV has crossed a voting rights threshold of 2.03% on January 6, 2023. This marks a decrease from a previous holding of 3.77%. Additionally, Aegon holds 0.25% voting rights through financial instruments, bringing the total to 2.28%. The notification to the Financial Conduct Authority (FCA) was completed on January 10, 2023. This change may indicate a shift in investor confidence or strategy regarding ANGLE plc's shares.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has appointed Juliet Thompson as a Non-Executive Director effective January 5, 2023. With extensive experience in the life sciences sector, she has advised on transactions worth over $4 billion. Thompson co-founded Code Securities and currently holds board positions at Indivior plc, Novacyt SA, and OrganOx. Both Thompson and ANGLE Chairman Garth Selvey emphasized her expertise in financing and corporate governance, which will support ANGLE's growth in the liquid biopsy market, particularly with its Parsortix system for cancer diagnostics.

ANGLE plc (OTCQX:ANPCY) announced significant business progress and an unaudited trading update for 2022, marking it as a breakthrough year with FDA clearance for its Parsortix cancer cell harvesting system. Key highlights include sensitivity and specificity results of 90% and 93%, respectively, in ovarian cancer studies. The company raised £20.1 million to support commercialization despite challenging market conditions. While 2022 revenue is anticipated just above £1 million and an operating loss of £22 million, angling for strong growth in 2023 remains a focus with a pipeline of new orders and partnerships.

ANGLE plc presented two posters at the San Antonio Breast Cancer Symposium 2022, showcasing the Parsortix PC1 Clinical System's ability to isolate circulating tumor cells (CTCs) from metastatic breast cancer patients. The studies involved 75 MBC patients and 71 healthy controls, demonstrating successful CTC capture through cytological and molecular evaluations. Key findings included the identification of CTCs in over 45% of MBC patients, with significant expression of CTC-related genes. This data supports the FDA classification of Parsortix as a Class II device, which is expected to drive commercial success.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced the issuance of 56,666 new ordinary shares due to the exercise of employee options. This will bring the total number of ordinary shares to 260,580,547, effective from December 7, 2022. The new shares rank equally with existing shares and have been submitted for trading on AIM. This issuance is part of the company's ongoing strategy to incentivize employees. The announcement also emphasizes the company's advancements in liquid biopsy technology, specifically through its FDA-cleared Parsortix system for capturing circulating tumor cells.

ANGLE plc has announced successful results from a multi-centre clinical study utilizing its Parsortix system to enrich circulating tumor cells (CTCs) from 207 metastatic breast cancer patients. The study demonstrated that CTCs could be analyzed using various downstream techniques, providing data for the successful De Novo FDA clearance of the Parsortix system on May 24, 2022. Notably, CTCs were detected in 48.5% of samples, highlighting the system's clinical utility for treatment monitoring and selection.

ANGLE plc presented its study at the International Society of Liquid Biopsy meeting, demonstrating the simultaneous analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a single blood sample. The proof of concept study confirmed that isolating CTCs does not compromise ctDNA quality, adding significant value for cancer characterization and patient monitoring. This multimodal approach enhances precision medicine by allowing genetic, transcriptional, and protein-level insights, positioning ANGLE competitively in an expanding liquid biopsy market.

ANGLE plc, a leading liquid biopsy company, has announced the issuance of 25,000 new ordinary shares following the exercise of employee options. The new shares will rank equally with existing shares, raising the total number of ordinary shares to 260,523,881. The shares are expected to be admitted for trading on AIM on October 27, 2022. This move aims to enhance liquidity and shareholder participation while aligning employee interests with company performance.